The Development of Novel HCV NS3-4A Protease Inhibitors

ISSN: 2211-3533 (Online)
ISSN: 2211-3525 (Print)

Volume 15, 2 Issues, 2017

Download PDF Flyer

Anti-Infective Agents

Formerly: Anti-Infective Agents in Medicinal Chemistry

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

The Development of Novel HCV NS3-4A Protease Inhibitors

Anti-Infective Agents, 11(2): 125-135.

Author(s): Chang-Ye Hui, Xiao-Bing Xie, Hong Cao and Sheng-He Huang.

Affiliation: Department of Microbiology, School of Public Health and Tropical Medicine, Southern Medical University, Tonghe, Guangzhou, 510515, China.


Continual genetic variation supports hepatitis C virus (HCV) persistent infection, a leading cause of cirrhosis and hepatocellular carcinoma. The current standard of care has limited efficacy and is associated with severe adverse effects. Efforts to improve patients’ outcomes have focused on the design and development of small molecule compounds targeted towards essential viral proteins. Following the clinical success of HIV protease inhibitors, the HCV NS3-4A protease domain emerged as one of the most successful antiviral drug targets. This mini-review describes several HCV protease inhibitors in the various stages of clinical trials, and discusses their antiviral activities, pharmacokinetic properties, side effects and resistance profiles.


Drug resistance, hepatitis C, HCV, NS3, protease inhibitor.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 2
First Page: 125
Last Page: 135
Page Count: 11
DOI: 10.2174/2211352511311020006
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science